Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

27 trials with published results (7%)

Research Maturity

194 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

1.5%

6 terminated out of 390 trials

Success Rate

97.0%

+10.5% vs benchmark

Late-Stage Pipeline

45%

177 trials in Phase 3/4

Results Transparency

14%

27 of 194 completed with results

Key Signals

27 with results97% success

Data Visualizations

Phase Distribution

311Total
Not Applicable (95)
Early P 1 (4)
P 1 (19)
P 2 (16)
P 3 (35)
P 4 (142)

Trial Status

Completed194
Unknown121
Recruiting34
Not Yet Recruiting17
Active Not Recruiting7
Withdrawn6

Trial Success Rate

97.0%

Benchmark: 86.5%

Based on 194 completed trials

Clinical Trials (390)

Showing 20 of 20 trials
NCT07439445Not ApplicableRecruitingPrimary

Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication

NCT05495854Not ApplicableTerminatedPrimary

New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool

NCT06382493Not ApplicableRecruitingPrimary

Tegoprazan-containing Sequential for H. Pylori

NCT07537634Phase 4RecruitingPrimary

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

NCT05332444Phase 4RecruitingPrimary

Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection

NCT06561711Phase 4CompletedPrimary

Optimization of Minocycline for Helicobacter Pylori Rescue Treatment

NCT07122284Completed

Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity

NCT07458490Not Yet Recruiting

Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound

NCT06340334Not ApplicableCompletedPrimary

Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

NCT06412588Not ApplicableCompletedPrimary

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

NCT06529159Not ApplicableRecruitingPrimary

H. Pylori Eradication With Argon Plasma During Endoscopy

NCT06340724Phase 3CompletedPrimary

Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication

NCT06156085Phase 4CompletedPrimary

Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy

NCT07408271CompletedPrimary

The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change

NCT07405697Phase 4Not Yet RecruitingPrimary

Fecal Molecular Susceptibility-guided Hp Rescue Therapy

NCT07358130Not ApplicableRecruitingPrimary

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy

NCT05647278Phase 4CompletedPrimary

Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)

NCT07312721Phase 4CompletedPrimary

Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis

NCT07285096RecruitingPrimary

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

NCT05926804Not ApplicableRecruitingPrimary

A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

Scroll to load more

Research Network

Activity Timeline